{'fraction_non_alphanumeric': 0.035053554040895815, 'fraction_numerical': 0.019474196689386564, 'mean_word_length': 4.976744186046512, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Therapy with interleukin 2 for chronic viral hepatitis].

We administered 250-10,000 u of recombinant interleukin 2 (r-IL2) for 1-4 weeks intravenously or intramuscularly to patients with chronic hepatitis B positive for serum HBe antigen as immunostimulants and studied the effect of r-IL2 for antiviral system. Serum ALT levels increased during the therapy and then decreased after the treatment. Activities of DNA-P were gradually reduced and became negative in 6 of 11 cases. Serum HBeAg decreased and anti-HBe increased during and after the therapy. Peripheral lymphocytes and eosinocytes increased during the therapy but returned to the pretreatment level after the therapy. TSI (%) increased rapidly and TS (%) decreased during infusion of r-IL2. However, TH/TS ratio increased after the infusion since TH (%) decreased gradually during the infusion of r-IL2. The r-IL2 therapy was useful for chronic hepatitis with serum HBe antigen as therapy with immunostimulant or treatment with biological response modifier (BRM).